These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 28068521)

  • 41. Cardiovascular risk factors and HIV disease.
    Fedele F; Bruno N; Mancone M
    AIDS Rev; 2011; 13(2):119-29. PubMed ID: 21587343
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Severe dyslipidemia and immune activation in HIV patients with dysglycemia.
    Jin C; Ji S; Xie T; Höxtermann S; Fuchs W; Lu X; Wu H; Cheng L; Skaletz-Rorowski A; Brockmeyer NH; Wu N
    HIV Clin Trials; 2016 Sep; 17(5):189-96. PubMed ID: 27409415
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Atherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy.
    Kaplan-Lewis E; Aberg JA; Lee M
    Curr HIV/AIDS Rep; 2016 Oct; 13(5):297-308. PubMed ID: 27562769
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virus.
    Beltrán LM; Rubio-Navarro A; Amaro-Villalobos JM; Egido J; García-Puig J; Moreno JA
    Vasc Health Risk Manag; 2015; 11():35-48. PubMed ID: 25609975
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Insulin resistance in treated HIV infection.
    Feeney ER; Mallon PW
    Best Pract Res Clin Endocrinol Metab; 2011 Jun; 25(3):443-58. PubMed ID: 21663838
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Approach to dyslipidemia, lipodystrophy, and cardiovascular risk in patients with HIV infection.
    Troll JG
    Curr Atheroscler Rep; 2011 Feb; 13(1):51-6. PubMed ID: 21181310
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lipodystrophy and metabolic syndrome in HIV-infected patients treated with antiretroviral therapy.
    Estrada V; Martínez-Larrad MT; González-Sánchez JL; de Villar NG; Zabena C; Fernández C; Serrano-Ríos M
    Metabolism; 2006 Jul; 55(7):940-5. PubMed ID: 16784968
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Increased cardiovascular disease risk in the HIV-positive population on ART: potential role of HIV-Nef and Tat.
    Wang T; Yi R; Green LA; Chelvanambi S; Seimetz M; Clauss M
    Cardiovasc Pathol; 2015; 24(5):279-82. PubMed ID: 26233281
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serum retinol-binding protein 4 correlates with obesity, insulin resistance, and dyslipidemia in HIV-infected subjects receiving highly active antiretroviral therapy.
    Han SH; Chin BS; Lee HS; Jeong SJ; Choi HK; Kim CO; Choi JY; Song YG; Lee HC; Kim JM
    Metabolism; 2009 Nov; 58(11):1523-9. PubMed ID: 19501863
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cardiovascular Disease in the Setting of Human Immunodeficiency Virus Infection.
    Pinto DSM; da Silva MJLV
    Curr Cardiol Rev; 2018 Mar; 14(1):25-41. PubMed ID: 29189172
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The safety and effectiveness of statins as treatment for HIV-dyslipidemia: the evidence so far and the future challenges.
    Ahmed MH; Al-Atta A; Hamad MA
    Expert Opin Pharmacother; 2012 Sep; 13(13):1901-9. PubMed ID: 22770622
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection.
    Samaras K
    J Antimicrob Chemother; 2008 Feb; 61(2):238-45. PubMed ID: 18070830
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lipid management in patients who have HIV and are receiving HIV therapy.
    Aberg JA
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):207-22. PubMed ID: 19217520
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dietary habits and their association with metabolic abnormalities in human immunodeficiency virus-related lipodystrophy.
    Hadigan C
    Clin Infect Dis; 2003; 37 Suppl 2():S101-4. PubMed ID: 12942382
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Metabolic and skeletal complications of HIV infection: the price of success.
    Morse CG; Kovacs JA
    JAMA; 2006 Aug; 296(7):844-54. PubMed ID: 16905789
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The study of fat redistribution and metabolic change in HIV infection (FRAM): methods, design, and sample characteristics.
    Tien PC; Benson C; Zolopa AR; Sidney S; Osmond D; Grunfeld C
    Am J Epidemiol; 2006 May; 163(9):860-9. PubMed ID: 16524955
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Cardiovascular risk factors associated with antiretroviral therapy].
    Pérez-Camacho I; Camacho A; Torre-Cisneros J; Rivero A
    Enferm Infecc Microbiol Clin; 2009 Sep; 27 Suppl 1():24-32. PubMed ID: 20172412
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Update on metabolic issues in HIV patients.
    Calvo M; Martinez E
    Curr Opin HIV AIDS; 2014 Jul; 9(4):332-9. PubMed ID: 24824886
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prevalence of diabetes mellitus, hyperinsulinaemia and metabolic syndrome among 755 adult patients with HIV-1 infection.
    Calza L; Masetti G; Piergentili B; Trapani F; Cascavilla A; Manfredi R; Colangeli V; Viale P
    Int J STD AIDS; 2011 Jan; 22(1):43-5. PubMed ID: 21364066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.